Linker engineering for fusion protein construction: Improvement and characterization of a GLP-1 fusion protein

Enzyme and Microbial Technology

Volumn 82, Issue , 2016, Pages 105-109

  Kong, Yuelin ^a   Tong, Yue ^a   Gao, Mingming ^b   Chen, Chen ^a   Gao, Xiangdong ^a   Yao, Wenbing ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b UNIVERSITY OF GEORGIA   (United States)

Author keywords

Adiponectin; Diabetes; GLP 1; Linker engineering

Indexed keywords

AFFINITY CHROMATOGRAPHY; CHEMICAL ACTIVATION; ENZYME ACTIVITY; ESCHERICHIA COLI; GLUCOSE; MAMMALS; MEDICAL PROBLEMS; PEPTIDES;

ADIPONECTIN; AMP-ACTIVATED PROTEIN KINASE; ANTI-DIABETIC DRUGS; GLP-1; GLUCAGON-LIKE PEPTIDE-1; LIPID METABOLISMS; NICKEL AFFINITIES; PROTEIN ENGINEERING;

PROTEINS;

ADIPONECTIN; ADIPONECTIN RECEPTOR; ANTIDIABETIC AGENT; GLP1 FUSION PROTEIN; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOSE; HYBRID PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; LIPID; NICKEL; UNCLASSIFIED DRUG; FAT INTAKE; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; OLIVE OIL; PEPTIDE; SYNTHETIC DNA;

AFFINITY CHROMATOGRAPHY; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; ESCHERICHIA COLI; GENE OVEREXPRESSION; GLUCOSE METABOLISM; IMMUNOBLOTTING; IN VITRO STUDY; LIPID METABOLISM; LUCIFERASE ASSAY; MALE; MOUSE; NONHUMAN; PROTEIN ENGINEERING; PROTEIN PHOSPHORYLATION; ANIMAL; BIOSYNTHESIS; BLOOD; C57BL MOUSE; DRUG EFFECTS; FAT INTAKE; GENETICS; HYPERGLYCEMIA; HYPERLIPIDEMIAS; METABOLISM; PHOSPHORYLATION; PROCEDURES; PROTEIN PROCESSING; REPORTER GENE;

ADIPONECTIN; AMP-ACTIVATED PROTEIN KINASES; ANIMALS; DIETARY FATS; ESCHERICHIA COLI; GENES, REPORTER; GENES, SYNTHETIC; GLUCAGON-LIKE PEPTIDE 1; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HYPERGLYCEMIA; HYPERLIPIDEMIAS; HYPOGLYCEMIC AGENTS; LIPIDS; MALE; MICE; MICE, INBRED C57BL; OLIVE OIL; PEPTIDES; PHOSPHORYLATION; PROTEIN ENGINEERING; PROTEIN PROCESSING, POST-TRANSLATIONAL; RECOMBINANT FUSION PROTEINS;

EID: 84947968373     PISSN: 01410229     EISSN: 18790909     Source Type: Journal    
DOI: 10.1016/j.enzmictec.2015.09.001     Document Type: Article

References (21)

1. Gautier J.-F., Choukem S.-P., Girard J. Physiology of incretins (GIP and GLP-1) and abnormalities in type 2 diabetes. Diabetes Metab. 2008, 34:S65-S72.
2. Heppner K.M., Perez-Tilve D. GLP-1 based therapeutics: simultaneously combating T2DM and obesity. Front. Neurosci. 2015, 9.
3. Baggio L.L., Huang Q., Brown T.J., Drucker D.J. A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis. Diabetes 2004, 53:2492-2500.
4. Glaesner W., Mark Vick A., Millican R., Ellis B., Tschang S.H., Tian Y., et al. Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein. Diabetes Metab. Res. Rev. 2010, 26:287-296.
5. Day J.W., Ottaway N., Patterson J.T., Gelfanov V., Smiley D., Gidda J., et al. A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. Nat. Chem. Biol. 2009, 5:749-757.
6. Finan B., Yang B., Ottaway N., Smiley D.L., Ma T., Clemmensen C., et al. A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents. Nat. Med. 2015, 21:27-36.
7. Schwenk R.W., Baumeier C., Finan B., Kluth O., Brauer C., Joost H.-G., et al. GLP-1-oestrogen attenuates hyperphagia and protects from beta cell failure in diabetes-prone New Zealand obese (NZO) mice. Diabetologia 2014, 1-11.
8. Gao M., Tong Y., Li W., Gao X., Yao W. Improving the anti-diabetic activity of GLP-1 by fusion with globular adiponectin. Artif. Cells Nanomed. Biotechnol. 2013, 41:159-164.
9. Zhao T., Lv J., Zhao J., Huang X., Xiao H. Expression of human globular adiponectin-glucagon-like peptide-1 analog fusion protein and its assay of glucose-lowering effect in vivo. Int. J. Med. Sci. 2011, 8:203.
10. Liu D.-G., Liu H.-L., Song T.-J., Huang H.-Y., Li X., Tang Q.-Q. Functional expression of the globular domain of human adiponectin in Pichia pastoris. Biochem. Biophys. Res. Commun. 2007, 363:769-775.
11. Okada-Iwabu M., Yamauchi T., Iwabu M., Honma T., Hamagami K.-i., Matsuda K., Yamaguchi M., Tanabe H., Kimura-Someya T., Shirouzu M. A small-molecule AdipoR agonist for type 2 diabetes and short life in obesity. Nature 2013, 503:493-499.
12. Hsieh J., Longuet C., Baker C., Qin B., Federico L., Drucker D., et al. The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice. Diabetologia 2010, 53:552-561.
13. George R.A., Heringa J. An analysis of protein domain linkers: their classification and role in protein folding. Protein Eng. 2002, 15:871-879.
14. Wang R., Xue Y., Wu X., Song X., Peng J. Enhancement of engineered trifunctional enzyme by optimizing linker peptides for degradation of agricultural by-products. Enzyme Microb. Technol. 2010, 47:194-199.
15. Lu P., Feng M.-G. Bifunctional enhancement of a β-glucanase-xylanase fusion enzyme by optimization of peptide linkers. Appl. Microbiol. Biotechnol. 2008, 79:579-587.
16. Argos P. An investigation of oligopeptides linking domains in protein tertiary structures and possible candidates for general gene fusion. J. Mol. Biol. 1990, 211:943-958.
17. de Maturana R.L., Willshaw A., Kuntzsch A., Rudolph R., Donnelly D. The isolated N-terminal domain of the glucagon-like peptide-1 (GLP-1) receptor binds exendin peptides with much higher affinity than GLP-1. J. Biol. Chem. 2003, 278:10195-10200.
18. Doyle M.E., Theodorakis M.J., Holloway H.W., Bernier M., Greig N.H., Egan J.M. The importance of the nine-amino acid C-terminal sequence of exendin-4 for binding to the GLP-1 receptor and for biological activity. Regul. Pept. 2003, 114:153-158.
19. Simonsen L., Holst J.J., Madsen K., Deacon C. The C-terminal extension of exendin-4 provides additional metabolic stability when added to GLP-1, while there is minimal effect of truncating exendin-4 in anaesthetized pigs. Regul. Pept. 2013, 181:17-21.
20. Tatarkiewicz K., Hargrove D., Jodka C., Gedulin B., Smith P., Hoyt J., et al. A novel long-acting glucose-dependent insulinotropic peptide analogue: enhanced efficacy in normal and diabetic rodents. Diabetes Obes. Metab. 2014, 16:75-85.
21. Wang S., Zheng C., Liu Y., Zheng H., Wang Z. Construction of multiform scFv antibodies using linker peptide. J. Genet. Genomics 2008, 35:313-316.